Industry: Plan to Expand Off-Label Uses in France Undermines EU Regulation

International Pharmaceutical Regulatory Monitor
A A
The French National Assembly last month approved a proposal that would allow doctors to use less expensive off-label drugs even if an approved therapy exists — sparking cries from European drugmakers that the government is placing cost savings over patient safety.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00